---
title: Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients
  with measurable residual disease
date: '2023-08-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37587502/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230817180900&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: FLYSYN monotherapy is safe and well-tolerated in AML patients
  with MRD. Early efficacy data are promising and warrant further evaluation in an
  up-coming phase II trial. Trial registration This clinical is registered on clinicaltrials.gov
  ...'
disable_comments: true
---
CONCLUSIONS: FLYSYN monotherapy is safe and well-tolerated in AML patients with MRD. Early efficacy data are promising and warrant further evaluation in an up-coming phase II trial. Trial registration This clinical is registered on clinicaltrials.gov ...